Part A: Emraclidine Followed by Itraconazole + Emraclidine for Healthy Subjects
This trial studies how medicines interact with each other in healthy adults to see how they affect each other.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
How many participants are being observed in this investigation?
"Affirmative. As per clinicaltrials.gov, this scientific experiment is still searching for participants and has been since July 21st 2023. The project seeks to recruit 60 patients from one medical site."
Is there an opportunity to join this research endeavor presently?
"Affirmative, clinicaltrials.gov shows that recruitment for this trial is in progress. It was first posted on July 21st 2023 and last modified a day later; 60 participants need to be sourced from one location."
Can those younger than sixty years of age participate in this research?
"This research study is only open to those aged 18-55. However, there are 53 studies available for minors and 374 trials accessible to seniors."
What criteria must be satisfied for individuals to partake in this medical experiment?
"For qualification, applicants must possess a healthy physique and have reached the age of consent but not exceeded 55 years old. This investigation requires 60 total participants."
To what extent is Part A: Emraclidine Followed by Itraconazole + Emraclidine deemed a safe course of treatment for individuals?
"Our team at Power believes that Part A: Emraclidine Followed by Itraconazole + Emraclidine holds a safety rating of 1 according to our scale, as this is only a Phase 1 trial and there is minimal evidence for effectiveness or risk management."